Ticker

Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript

Cybin Inc. (OTCMKTS:CYBN - Get Free Report)'s stock price traded up 1.2% on Friday. The stock traded as high as $8.38 and last traded at $8.28. 717,287 shares were traded during mid-day trading, an increase of 42% from the average session volume of 503,386 shares. The stock had previously closed at $8.18. Wall Street

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has launched an at-the-market equity program (the “ATM Program”) to allow Cybin to issue and sell up to US$100,000,000 of…

Cybin Inc. (NYSEAMERICAN:CYBN - Get Free Report)'s stock price rose 4.4% on Monday. The stock traded as high as $8.74 and last traded at $8.71. Approximately 1,477,533 shares were traded during mid-day trading, an increase of 90% from the average daily volume of 776,156 shares. The stock had previously closed at $8.34. Analyst Upgrades

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market (“Nasdaq”) from the NYSE American LLC (“NYSE American”). The Company…